A

Systemic therapy is required for erythrodermic psoriasis; methotrexate is one of the established first-line systemic agents, whereas topical or systemic corticosteroids and coal-tar preparations are either adjunctive or potentially harmful because of rebound flares [Rosenbach et al., 2010, PMID 19665821].